In particular, our findings suggest that rNEN-L patients diagnosed with lymph node metastases may be more sensitive to RET inhibitors (sorafenib, vandetinib) as well as PI3K/AKT/MTOR and JAK inhibitors. This evidence concerns the gene RET and metastatic malignant neoplasm in the lymph nodes.